Shinichi Higashiue

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Sonia S. Anand, Jackie Bosch, John W. Eikelboom et al. · The Lancet · 2017 · 880 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Stuart J. Connolly, John W. Eikelboom, Jackie Bosch et al. · The Lancet · 2017 · 756 citations · Full text

Medicine, Cardiology, Pharmacology +13

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 311 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta et al. · The Lancet · 2019 · 210 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event

Carolyn S.P. Lam, Anna Giczewska, Karen Sliwa et al. · JAMA Cardiology · 2020 · 82 citations · Full text

Medicine, Cardiology, Pharmacotherapy +13